NERV — Minerva Neurosciences, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1598646 ·
Last close
$3.98
Market Cap
$185.42M
52W High
$6.50
52W Low
$3.85
ADV30
318,000
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -16,671,552 | -125,404,384 | 94,027,156 | 32,659,770 | 348,041,016 |
| Dec 2025 | 0 | — | -4,981,589 | -283,667,663 | 97,968,888 | 82,301,813 | 238,716,970 |
| Sep 2025 | 0 | — | -2,844,348 | -2,743,954 | 28,092,052 | 12,286,646 | 62,672,322 |
| Jun 2025 | 0 | — | -3,374,149 | -3,258,588 | 30,419,645 | 15,247,910 | 62,528,858 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-13,510,936
Investing CF
$0
Financing CF
$74,495,907
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-26.80
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-688,799,740
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-293,423,177
Pretax Income TTM
$-293,423,177
Interest Exp TTM
$0
Analysts
3
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -15,102,970 | -293,423,177 | 97,968,888 | 238,716,970 | — | -13,510,936 |
| Dec 2024 | 0 | -21,848,386 | 1,438,865 | 37,143,744 | 62,836,844 | — | -19,550,567 |
| Dec 2023 | 0 | -23,119,576 | -30,005,353 | 56,899,750 | 85,357,240 | — | -14,784,732 |
| Dec 2022 | 0 | -25,231,326 | -32,108,676 | 55,087,233 | 75,111,452 | — | -24,645,143 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.48
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NBP | NovaBridge Biosciences | $185.04M | $1.60 | — |
| IMUX | IMMUNIC, INC. | $190.29M | $13.97 | — |
| WHWK | Whitehawk Therapeutics, Inc. | $190.39M | $3.85 | — |
| CAMP | Camp4 Therapeutics Corp | $179.14M | $3.45 | — |
| ANTX | AN2 Therapeutics, Inc. | $192.69M | $5.35 | — |
News headlines (Yahoo Finance, 1h cache)
Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs
2026-06-01 20:05 · Yahoo
All You Need to Know About Minerva Neurosciences (NERV) Rating Upgrade to Buy
2026-05-20 16:00 · Yahoo
Minerva Neurosciences (NERV) Loses 37.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
2026-05-20 13:35 · Yahoo
Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference
2026-05-18 20:05 · Yahoo
Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates
2026-05-05 12:00 · Yahoo
NRG Fusion Market Competitive Landscape Report 2026 Featuring Zensun (Shanghai) Sci & Tech, Salubris Biotherapeutics, Hummingbird Bioscience, Minerva Neurosciences
2026-04-13 09:08 · Yahoo
Minerva Announces Leadership Transition
2026-04-02 20:05 · Yahoo
Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia
2026-03-31 20:05 · Yahoo
Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026
2026-03-25 20:05 · Yahoo
Minerva Neurosciences Touts Roluperidone Data, FDA-Aligned Trial Plan for Schizophrenia Symptoms
2026-03-21 05:02 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.